Fabino Life Sciences IPO Basis of Allotment

Our Company was incorporated as "Fabino Life Sciences Private Limited" on October 27, 2011 under the Companies Act, 1956 with the Registrar of Companies, Delhi and Haryana bearing Registration No. 226781. Subsequently, the status of our Company was changed to public limited company and the name of our Company was changed to "Fabino Life Sciences Limited" vide Special Resolution dated March 03, 2015. A fresh certificate of incorporation consequent to conversion was issued on March 21,2015 by the Registrar of Companies, Delhi. The Company's Corporate Identity Number is U24100DL2011PLC226781. For further details pertaining to the change of name of our Company and the change in Registered Office, please refer the chapter "History and Certain Corporate Matters" on page no. 107 of this Prospectus.

INITIAL PUBLIC ISSUE OF 9,00,000 EQUITY SHARES OFRS. 10 EACH ("EQUITY SHARES") OF FABIN0 LIFE SCIENCES LIMITED ("FLSL" OR THE "COMPANY") FOR CASH AT A PRICE OF RS. 36 PER SHARE (THE "ISSUE PRICE"), AGGREGATING TO RS. 324.00 LAKHS ("THE ISSUE"), OF WHICH 48,000 EQUITY SHARES OF RS. 10 EACH WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 8,52,000 EQUITY SHARES OF RS. 10 EACH IS HEREINAFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 42.86% AND 40.57%, RESPECTIVELY OFTHE POST ISSUE PAID UP EQUITY SHARE CAPITAL OFTHE COMPANY.

The Equity Shares of the Company are proposed to be listed on the SME Platform of BSE Limited, in terms of the Chapter IX of the SEBI (ICDR) Regulations, 2018 as amended from time to time. Our Company has received an In-Principle approval from BSE for the listing of the Equity Shares pursuant to letter dated December 21, 2021. BSE shall be the Designated Stock Exchange for the purpose of this Issue. The trading is proposed to be commenced on January 13, 2022 (Subject to receipt of listing and trading approvals from the BSE Limited).

The Issue is being made through the Fixed Price process, the allocation in the Net Issue to the Public category shall be made pursuant to Regulation 253(2) of the SEBI (ICDR) Regulations, 2018, as amended from time to time, wherein a minimum of 50% of the Net Issue of shares to the Public shall initially be made available for allotment to Retail Individual Investors. The balance of Net Issue of Shares to the public shall be made available for allotment to Individual Applicants other than Retail Individual Investors and other Investors, including Corporate Bodies / Institutions irrespective of number of shares applied for. If the Retail Individual Investor category is entitled to more than 50% on proportionate basis, they shall be allotted that higher percentage. Linder subscription, if any, in any of the categories, would be allowed to be met with spill-over from any of the other categories or a combination of categories at the discretion of our Company in consultation with the Lead Manager and the Designation Stock Exchange. Such inter-se spill over, if any, would be affected in accordance with applicable laws, rules, regulations and guidelines. All potential investors shall participate in the Issue only through an Application Supported by Blocked Amount ("ASBA") process including through UPI mode (as applicable) by providing details of the irrespective bank accounts and/ or UPI IDs, in case of RIIs, if applicable, which will be blocked by the Self Certified Syndicate Banks ("SCSBs")

SUBSCRIPTION DETAILS

The Net Issue has received 1529 applications for 59,01,000 Equity Shares resulting in 6.56 times subscription. The details of the applications received in the Net Issue (before and after technical rejections & withdrawal) are as follows:

Detail of the Applications Received

Note: The Issue also includes 48,000 Equity Shares reserved for Market Maker, which was subscribed by 1.00 times and there were no Technical Rejection & any withdrawal.

In the event of over subscription, the allotment will be made on a proportionate basis in marketable lots. There was over subscription of 10,62,000 Equity Shares in other than Retail Individual Category & 39,87,000 Equity Shares in Retail Category. The Basis of Allotment was finalised in consultation with the Designated Stock Exchange - BSE Limited on January 10, 2022.

A) Allocation to Market Maker (After Technical Rejections & Withdrawals): The Basis of Allotment to the Market Maker, at the Issue Price of Rs. 36 per Equity Share, was finalised in consultation with BSE. The category was subscribed by 1.00 times. The total number of shares allotted in this category is 48,000 Equity Shares. The category-wise details of the Basis of Allotment are as under:

B) Allocation to Retail Individual Investors (After Technical Rejections & Withdrawals): The Basis of Allotment to the Retail Individual Investors, at the Issue Price of Rs. 36 per Equity Share, was finalised in consultation with BSE. Pursuant to Regulation 253(2) of the SEBI (ICDR) Regulations, 2018, the total number of shares allocated in this category is 6,03,000 Equity Shares. The category was subscribed by 5.71 times. The category-wise details of the Basis of Allotment are as under:

C) Allocation to Other than Retails Category (After Technical Rejections & Withdrawals): The Basis of Allotment to the Non-Retail Investors, at the Issue Price of Rs. 36 per Equity Share, was finalised in consultation with BSE. Pursuant to Regulation 253(2) of the SEBI (ICDR) Regulations, 2018, the total number of shares allocated in this category is 2,49,000 Equity Shares. The category was subscribed by 5.75 times. The category-wise details of the Basis of Allotment are as under:

The Board of Directors of the Company at its meeting held on January 10, 2022, has taken on record the Basis of Allotment of Equity Shares, as approved by the Designated Stock Exchange viz. BSE and has authorized the corporate action for the allotment of the Equity Shares to various successful applicants.

The CAN and allotment advice and / or notices shall be dispatched to the address of the investors as registered with the depositories on or before January 12, 2022. Further, the instructions to Self Certified Syndicate Banks will be processed on or before January 12, 2022 for unblocking of funds. The Equity Shares allotted to successful applicants are being credited to their beneficiary accounts subject to validation of the account details with the depositories concerned. In case the same is not received within prescribed time, investors may contact the Registrar to the Issue at the address given below. The Company is taking steps to get the Equity Shares admitted for trading on the SME Platform of BSE Limited within 6 working days from the Closure of the Issue. The trading is proposed to be commenced on January 13, 2022 subject to receipt of listing and trading approvals from BSE Limited.

Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Prospectus dated December 27, 2021 ("Prospectus").

INVESTORS PLEASE NOTE

The details of the allotment made has been hosted on the website of the Registrar to the Issue, Bigshare Services Private Limited at Website: www.bigshareonline.com . All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/Sole Applicant, Serial number of the Application Form, Number of Shares Applied for and Bank Branch where the Application had been lodged and payment details at the address given below:

	BIGSHARE SERVICES PRIVATE LIMITED
	1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East, Mumbai - 400 059
	Tel. No.: +91 22 6263 8200
	Email: ipo@bigshareonline.com
	Website: www.bigshareonline.com
	Contact Person: Babu Raphael

	For Fabino Life Sciences Limited
	On Behalf of the Board of Directors
Place: New Delhi	Sd/-
Date: January 12, 2022	Jt. Managing Director

LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARE ON LISTING OR THE BUSINESS PROSPECTS OF FABINO LIFE SCIENCES LIMITED

FABINO LIFE SCIENCES LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make a Public Issue of its Equity Shares and has filed the Prospectus with the Registrar of Companies, New Delhi. The Prospectus shall be available on the websites of the Company, the BSE and the Lead Manager at www.fabinolife.com, www.bseindia.com and www.afsl.co.in respectively. Applicants should note that investment in equity shares involves a high degree of risk and for details relating to the same, seethe Prospectus, including, the section titled "Risk Factors" beginning on page no. 18 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold (i) within the United States to persons reasonably believed to be qualified institutional investors (as defined in Rule 144A under the U.S. Securities Act) pursuant to Rule 144A under the U.S. Securities Act and (ii) outside the United States in offshore transactions in reliance on Regulations under the U.S. Securities Act and applicable laws of the jurisdictions where such offers and sales occur.